According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “
A number of other brokerages have also commented on CMRX. Wedbush initiated coverage on shares of Chimerix in a research report on Wednesday, March 31st. They set an “outperform” rating and a $21.00 target price on the stock. Jefferies Financial Group began coverage on Chimerix in a report on Wednesday, March 31st. They set a “buy” rating and a $21.00 price objective on the stock. Jonestrading reiterated a “buy” rating and issued a $14.00 target price on shares of Chimerix in a report on Monday, April 12th. HC Wainwright raised their price target on Chimerix from $7.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 11th. They noted that the move was a valuation call. Finally, Maxim Group began coverage on Chimerix in a report on Thursday, April 29th. They issued a “buy” rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $16.96.
Chimerix (NASDAQ:CMRX) last issued its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.01. The firm had revenue of $1.12 million during the quarter, compared to analyst estimates of $1.59 million. Chimerix had a negative net margin of 321.31% and a negative return on equity of 36.57%. On average, equities analysts anticipate that Chimerix will post -0.71 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pacer Advisors Inc. bought a new stake in Chimerix during the first quarter valued at about $29,000. Lindbrook Capital LLC bought a new stake in shares of Chimerix in the 4th quarter valued at about $31,000. Meeder Asset Management Inc. bought a new stake in shares of Chimerix in the 1st quarter valued at about $45,000. Dorsey Wright & Associates purchased a new position in shares of Chimerix in the 1st quarter worth approximately $46,000. Finally, SG Americas Securities LLC bought a new position in shares of Chimerix during the 4th quarter worth approximately $49,000. 45.41% of the stock is owned by hedge funds and other institutional investors.
Chimerix Company Profile
Chimerix, Inc, a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 a program for potentially treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients.
Recommended Story: Why investors pay attention to retained earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.